Secura Bio

Company snapshot

Secura Bio was established in 2019 with a singular mission: to close the gap between innovative oncology therapies and the patients who need them most. Our high-touch approach is informed by our decades of experience shaping the impact of oncology’s largest clinical and market opportunities. We leverage our experience to embrace the challenges of commercializing and developing therapies for the mo

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Secura Bio. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Secura Bio.

1. Jun 8, 2026 Clinical update

   SBI-0145-304 — Phase 3

View all clinical trial activity →

• What is Secura Bio?

  Secura Bio is a pharma organization headquartered in GB. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (1).

• Is Secura Bio publicly traded?

  Secura Bio appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Secura Bio develop or market?

  We link 7 drug profile(s) where Secura Bio is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/secura-bio-limited#company-drugs.

• What are the latest developments for Secura Bio?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Secura Bio focus on?

  No specific therapeutic focus areas are currently identified for Secura Bio in our database.